Lung cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 70 years, no gender-limited physical examination chest CT screening no positive nodules (positive nodules or calcified nodules; 2. Indeterminate nodules or non-calcified nodules, such nodules determine the follow-up principle according to the nature and size of the nodules, and determine whether to carry out clinical intervention according to the growth characteristics of the nodules during follow-up); 3. Volunteers who plan to undergo pulmonary nodule surgery.
Exclusion criteria
Exclusion criteria: 1. Patients with myocardial infarction, stroke and shock in the past 3 months; 2. Patients with severe cardiac insufficiency, severe arrhythmia, unstable angina pectoris, severe hypertension and hypertensive crisis (systolic blood pressure>200 mmHg diastolic blood pressure>100 mmHg) or patients with thoracoabdominal aortic aneurysm in the past 4 weeks; 3. Patients with pneumothorax and pneumothorax within 1 month after healing; 4. Patients with severe bullae, severe hypoxemia and severe respiratory failure; 5. Large hemoptysis in the past 4 weeks, seizures requiring drug treatment, on the day of pulmonary function test, on the day of fiberoptic bronchoscopy, and hemoptysis after biopsy (including blood in sputum); 6. Severe hyperthyroidism, low immunity, susceptible to infection; 7. Frail or myasthenia gravis patients; 8. Those who cannot cooperate, such as patients with severe cough, hemiplegia, facial paralysis, cerebral palsy, intellectual disability, deaf patients, those with a history of allergy to PE materials, pregnant or breastfeeding women; 9. The investigators believe that they are not suitable to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| micro Ribonucleic Acid markers in lung cancer; | — |
Countries
China
Contacts
Sichuan Cancer Hospital and Institute